Suppr超能文献

幽门螺杆菌对使用促动力药物西沙必利治疗的非溃疡性消化不良患者症状改善无影响。

Lack of effect of Helicobacter pylori on symptom improvement with a prokinetic medication, cisapride, in patients with non-ulcer dyspepsia.

作者信息

Gonlachanvit Sutep, Mahachai Varocha, Chaiwatanarat Tawatchai, Kullavanijaya Pinit

机构信息

Department of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.

出版信息

J Med Assoc Thai. 2005 May;88(5):660-7.

Abstract

OBJECTIVE

This study was undertaken to determine whether H. pylori infection has an effect on the improvement of dyspeptic symptoms in response to a prokinetic agent, cisapride, in patients with non-ulcer dyspepsia (NUD).

MATERIAL AND METHOD

35 NUD patients (16 M, 19 F) who had no underlying medical condition and negative upper endoscopy were included in the present study. Each patient received a 2-wk treatment of cisapride (Prepulsid, 10 mg, tid ac). H. pylori infection was determined using a rapid urease test (CLO test). Gastric emptying (GE) scintigraphy and dyspeptic symptom scores were evaluated before and at the end of the treatment. GE was evaluated in 22 healthy volunteers as normal controls.

RESULTS

Half time (T1/2) GE of NUD patients was 90.9 +/- 28 min which was significantly longer than controls (77.6 +/- 14 min; p < 0.05) and was shortened to 73.6 +/- 22 min (p < 0.0001) at the end of the treatment. Cisapride significantly improved total dyspeptic symptom scores [7 (2-18) to 3 (0-11), p < 0.0001]. The symptom score improvement was not affected by H. pylori infection [H. pylori positive: 6 (2-18) to 2.5 (0-9), p < 0.0001; H. pylori negative: 9 (4-16) to 3 (0-11), p < 0.0001] or GE status [delayed GE: 10 (5-16) to 3 (15), p < 0.05; non delayed GE: 6 (2-18) to 2 (0-11); p < 0.0001].

CONCLUSIONS

Cisapride improves dyspeptic symptoms regardless of H. pylori and GE status. These results suggest that gastric emptying and H. pylori infection are not essential to determine prior to prescribing a prokinetic agent, cisapride, in patients with NUD.

摘要

目的

本研究旨在确定幽门螺杆菌感染对非溃疡性消化不良(NUD)患者使用促动力药西沙必利后消化不良症状改善情况是否有影响。

材料与方法

本研究纳入35例无基础疾病且上消化道内镜检查阴性的NUD患者(男16例,女19例)。每位患者接受为期2周的西沙必利治疗(普瑞博思,10毫克,每日三次,饭前服用)。采用快速尿素酶试验(CLO试验)检测幽门螺杆菌感染情况。在治疗前及治疗结束时评估胃排空(GE)闪烁扫描及消化不良症状评分。以22名健康志愿者作为正常对照评估胃排空情况。

结果

NUD患者的胃排空半衰期(T1/2)为90.9±28分钟,显著长于对照组(77.6±14分钟;p<0.05),治疗结束时缩短至73.6±22分钟(p<0.0001)。西沙必利显著改善了总的消化不良症状评分[从7(2 - 18)降至3(0 - 11),p<0.0001]。症状评分的改善不受幽门螺杆菌感染情况[幽门螺杆菌阳性:从6(2 - 18)降至2.5(0 - 9),p<0.0001;幽门螺杆菌阴性:从9(4 - 16)降至3(0 - 11),p<0.0001]或胃排空状态[胃排空延迟:从10(5 - 16)降至3(1 - 5),p<0.05;胃排空未延迟:从6(2 - 18)降至2(0 - 11);p<0.0001]的影响。

结论

无论幽门螺杆菌感染情况及胃排空状态如何,西沙必利均可改善消化不良症状。这些结果表明,在为NUD患者开具促动力药西沙必利之前,无需先确定胃排空及幽门螺杆菌感染情况。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验